Research - Bellicum is a cell therapy developer with a pipeline of early therapeutics, including the now-ubiquitous chimeric antigen receptor T cell candidates (a la Juno Therapeutics (JUNO) and Kite (KITE)) and T cell receptor (TCR) candidates, neither of which will enter the clinic until next year.
Premium: Read NowResearch - These events set 1H16 up as a make-or-break period for Marinus. The company has enough cash ($34.5 million at September 30) to get through 2016
Premium: Read NowResearch - The breakout we’ve been looking for from the biotech sector (NASDAQ’s Biotech Index Fund (IBB) is underway coming out of large-cap bio and pharma earnings over the last two days. Beats across the board have investors enthused – at least for now – about the sector as a whole.
Premium: Read NowResearch - Despite an onslaught of ominous headlines -- allegations of fraud at Valeant Pharamceuticals (VRX) and continued backlash over increasing drug prices -- biotech stocks have held steady over the last month.
Premium: Read NowResearch - Shares of bluebird bio (BLUE) tumbled 15% mid-day when the company said at a medical conference that a beta-thalassemia patient who received Lentiglobin’s predecessor therapeutic … Continue Reading
Premium: Read NowResearch - Positive top-line results from SOLITAIRE-IV, with some confounding safety outcomes, had Cempra Inc (CEMP) trading down on Friday morning by 25%.
Premium: Read NowResearch - Transition Therapeutics (TTHI) said in a press release Thursday morning that after further review of the failed phase 2/3 study of ELND005 in Alzheimer's disease patients with agitation and aggression, the company identified a sub-population in which patients saw a significant clinical benefit on ELND00.
Premium: Read Now
